Literature DB >> 17488253

Domperidone: review of pharmacology and clinical applications in gastroenterology.

Savio C Reddymasu1, Irfan Soykan, Richard W McCallum.   

Abstract

Domperidone is a dopamine-2 receptor antagonist. It acts as an antiemetic and a prokinetic agent through its effects on the chemoreceptor trigger zone and motor function of the stomach and small intestine. Unlike metoclopramide, it does not cause any adverse neurological symptoms as it has minimal penetration through the blood-brain barrier. It thus provides an excellent safety profile for long-term administration orally in the recommended doses. Domperidone is widely used in many countries and can now be officially prescribed to patients in the United States by an investigational new drug application for the treatment of gastroparesis and any condition causing chronic nausea and vomiting. In view of this additional clinical exposure of domperidone to a new generation of gastroenterologists and other specialists, the purpose of this timely review is to revisit the pharmacology, clinical application, and safety profile of this beneficial medication.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17488253     DOI: 10.1111/j.1572-0241.2007.01255.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  62 in total

1.  Case series: paradoxical action of domperidone leads to increased vomiting.

Authors:  Marco Pozzi; Sandra Strazzer; Federica Locatelli; Sara Galbiati; Francesca Formica; Luciano Maestri; Emilio Clementi; Sonia Radice
Journal:  Eur J Clin Pharmacol       Date:  2012-06-16       Impact factor: 2.953

2.  Oral domperidone has no additional effect on chronic functional constipation in children: a randomized clinical trial.

Authors:  Seyed Mohsen Dehghani; Mehrdad Askarian; Heidar Ali Kaffashan
Journal:  Indian J Gastroenterol       Date:  2013-08-31

3.  Ethnic, Racial, and Sex Differences in Etiology, Symptoms, Treatment, and Symptom Outcomes of Patients With Gastroparesis.

Authors:  Henry P Parkman; Goro Yamada; Mark L Van Natta; Katherine Yates; William L Hasler; Irene Sarosiek; Madhusudan Grover; Ron Schey; Thomas L Abell; Kenneth L Koch; Braden Kuo; John Clarke; Gianrico Farrugia; Linda Nguyen; William J Snape; Laura Miriel; James Tonascia; Frank Hamilton; Pankaj J Pasricha; Richard W McCallum
Journal:  Clin Gastroenterol Hepatol       Date:  2018-11-04       Impact factor: 11.382

Review 4.  Endoscopic botox injections in therapy of refractory gastroparesis.

Authors:  Andrew Ukleja; Kanwarpreet Tandon; Kinchit Shah; Alicia Alvarez
Journal:  World J Gastrointest Endosc       Date:  2015-07-10

Review 5.  A Review of Herbal and Pharmaceutical Galactagogues for Breast-Feeding.

Authors:  Alessandra N Bazzano; Rebecca Hofer; Shelley Thibeau; Veronica Gillispie; Marni Jacobs; Katherine P Theall
Journal:  Ochsner J       Date:  2016

Review 6.  Gastroparesis: Medical and Therapeutic Advances.

Authors:  Christopher M Navas; Nihal K Patel; Brian E Lacy
Journal:  Dig Dis Sci       Date:  2017-07-18       Impact factor: 3.199

Review 7.  Pharmacologic Treatment for Pediatric Gastroparesis: A Review of the Literature.

Authors:  Emma M Tillman; Keaton S Smetana; Likeselam Bantu; Merrion G Buckley
Journal:  J Pediatr Pharmacol Ther       Date:  2016 Mar-Apr

Review 8.  Parkinson disease: an update.

Authors:  Steven J Frucht
Journal:  Neurologist       Date:  2004-07       Impact factor: 1.398

9.  Anticholinergic syndrome following an unintentional overdose of scopolamine.

Authors:  Carmela E Corallo; Ann Whitfield; Adeline Wu
Journal:  Ther Clin Risk Manag       Date:  2009-09-15       Impact factor: 2.423

10.  Memory encoding and dopamine in the aging brain: a psychopharmacological neuroimaging study.

Authors:  Alexa M Morcom; Edward T Bullmore; Felicia A Huppert; Belinda Lennox; Asha Praseedom; Helen Linnington; Paul C Fletcher
Journal:  Cereb Cortex       Date:  2009-07-22       Impact factor: 5.357

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.